pntd.0008143.g004.tif (168.87 kB)
Download file

Survival curves and cumulative mean clinical scores of tested groups.

Download (168.87 kB)
figure
posted on 2020-03-11, 17:42 authored by Benjamin Gutjahr, Markus Keller, Melanie Rissmann, Felicitas von Arnim, Susanne Jäckel, Sven Reiche, Reiner Ulrich, Martin H. Groschup, Martin Eiden

(A) Efficacy of antibody protection was assessed by survival analysis. (A) Kaplan-Meier log rank test was performed; n.s. between mAb-Gn3-treated (T1/T2) and PBS control, p<0.001 between mAb-Gn3-Gn32-treated (T1) and PBS control, p<0.001 between mAb-Gn3-Gn32-treated (T2) and PBS control, n.s. between mAb-Gn3-Gn32-treated (T1/T2) and Gn3 (T1/T2). (B) Clinical scores were monitored and recorded daily after infection. n.s. not significant.

History